about
Variable selection and pattern recognition with gene expression data generated by the microarray technology.Novel application of a fibrin cell block method to evaluate melanocytic cell populations.Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.Empirical methods for controlling false positives and estimating confidence in ChIP-Seq peaksCellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.Colonic adenoma risk in familial colorectal cancer--a study of six extended kindredsSerum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinomaA genome-wide study replicates linkage of 3p22-24 to extreme longevity in humans and identifies possible additional loci.PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans.Clinical germline genetic testing for melanoma.Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Metabolic complications with the use of mTOR inhibitors for cancer therapyQuantitative insight into proliferation and differentiation of oligodendrocyte type 2 astrocyte progenitor cells in vitroMicrosatellites as EWS/FLI response elements in Ewing's sarcomaOncogenetic tree model of somatic mutations and DNA methylation in colon tumors.Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors.A population-based study of childhood cancer survivors' body mass index.Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of QigongA decade of melanomas: identification of factors associated with delayed detection in an academic group practice.Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp.Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study.TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors.Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaEWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations.A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.Effect of brachytherapy technique and patient characteristics on cervical cancer implant dosimetry.Recent trends in applicants and the matching process for the integrated plastic surgery match.Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy.Estimating an oncogenetic tree when false negatives and positives are present.
P50
Q30676405-D2B2EB95-743E-4435-8572-CA6346633784Q31027702-24CB59F0-9B61-4F67-8AF5-0C98FAFA1504Q33365279-C7C94DB5-548D-4008-918B-6DD053D9FB0CQ33367980-3050E725-012F-4362-8834-304CB9E12A5AQ33390488-6854F7A2-72E5-434A-B03F-B909A46367BDQ33565776-3D5F041F-EC47-4B1D-9254-8CE3C0CAA070Q33730680-AA540555-0F0A-40DB-94AA-8B7078EF0B28Q33917739-C302EB81-C84E-43AE-A4B1-8F9E66483694Q33929696-A19FD9FD-CE8A-471C-8613-1910671EBCE1Q34067803-B73EAB61-2D01-47E8-8D3B-DC795399DF75Q34185657-082E887D-9E0C-43DE-B749-7917B8A2920BQ34233710-41883275-96EA-4109-82C4-1817E68F31FBQ34433549-C69312D4-3A9C-4E49-887E-82AD80B1BE7AQ34786695-62C9B1E8-D516-42E8-B579-6DC0419D03CDQ35744780-60FC7792-D7C2-466F-83A2-C088F8360DB8Q35761693-CAEC4A19-4628-4FEA-8897-E5BC40B65A28Q35913234-2F0943A3-3ABF-4921-8F30-D3231C7AF138Q36474762-168A5154-27C6-4114-9E51-FA1F85D33B8CQ36553511-933E03C6-9D5E-4426-9B01-4628363B7740Q36553517-21AE7926-45A6-416F-B289-AB651553B662Q36730516-7F4CE2B3-EBD0-415A-9CB7-EB82914100EAQ36786777-AFD67C1E-3564-432F-B7E8-456F685D873CQ37091527-86F48172-31B2-4925-A0CF-718155CEFB39Q37130537-68D6C49A-0D70-41C8-830A-402BCAF490B3Q37318607-0136D595-E8C2-49BE-B29D-809697DEE498Q37553209-FDB1581D-C0D8-4CDC-B4D7-EA0A9776F5A1Q37622683-DECF9D72-6786-463D-B57D-015C44AD4120Q37905914-4FE18996-6E24-43D6-8FA0-27FCF65F9D21Q38174363-F2169C66-5181-4A44-B1C0-C0C68A94F4E0Q38452219-8CFB1CE8-96CC-4ABA-8D70-88CD97E6A67FQ39433556-4434274B-2C95-4BE6-A023-150295DD467FQ40748869-DEF0BC7D-B5A7-4D29-86EA-6AB3D8CA3123Q41768357-758AF69F-42C5-44DA-9143-4AFCAAF1511EQ42224745-9B9A766D-68C1-4F97-9D04-CDDA3E9F2631Q46000912-28F6A3C3-B02D-4299-880F-65A1B2D97A59Q46140481-E9B1D6EA-868A-4EE2-AD10-47A4A10F3E00Q46553138-D67FAD84-D6BF-4E67-8539-17AF41E5D0A7Q46721440-D2D712CE-8351-4DE1-B735-AAFA70D33B78Q46937261-218F00D6-091A-4272-8F38-133258373DABQ47571437-FF903CE7-D560-4535-9063-1AC1DB51DC35
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kenneth Boucher
@ast
Kenneth Boucher
@en
Kenneth Boucher
@es
Kenneth Boucher
@nl
Kenneth Boucher
@sl
type
label
Kenneth Boucher
@ast
Kenneth Boucher
@en
Kenneth Boucher
@es
Kenneth Boucher
@nl
Kenneth Boucher
@sl
prefLabel
Kenneth Boucher
@ast
Kenneth Boucher
@en
Kenneth Boucher
@es
Kenneth Boucher
@nl
Kenneth Boucher
@sl
P106
P1153
7004912513
P21
P31
P496
0000-0003-2833-0127